SUPPLEMENTARY DATA

Supplementary Table 1. Change in nausea during exenatide and placebo treatment periods.

Outcome	Treatment	Estimated Δ During Treatment Period (0-16 wks)	Lower limit (95% confidence)	Upper limit (95% confidence)	p-value
Δ Nausea wk 0-2	Exenatide	0.89	0.32	1.46	**0.031**
	Placebo	0	-0.56	0.57	
Δ Nausea wk 0-4	Exenatide	1.23	0.63	1.84	**0.002**
	Placebo	-0.03	-0.61	0.55	
Δ Nausea wk 0-8	Exenatide	0.66	0.22	1.1	**0.007**
	Placebo	-0.12	-0.53	0.3	
Δ Nausea wk 0-12	Exenatide	0.57	-0.04	1.18	**0.074**
	Placebo	-0.13	-0.7	0.45	
Δ Nausea wk 0-16	Exenatide	0.47	-0.02	0.96	0.186
	Placebo	0	-0.46	0.47	

Nausea was assessed using a 10cm horizontal visual analog scale (VAS). Note that 0-2 weeks reflects initial dose of exenatide or placebo (5 µg twice daily) while all other intervals reflect 10 µg twice daily. A negative value indicates a decrease in nausea. All parameters were reported in the morning in the fasted state. Estimated deltas are reported from a least squared means model to account for any period (order) effect.

SUPPLEMENTARY DATA

Supplementary Figure 1. Study Scheme